EBR Systems Inc (ASX:EBR)

ALERT: Price-sensitive ASX Announcement for EBR

Current share price for EBR : $0.375 -0.53 (-58.56%)⁺

Announcement

First implant in the Totally Leadless CRT (TLC-AU) Study

Release

12 Dec 2025 8:52AM

Price at Release

$0.905

Full Release

Summary

EBR Systems, Inc. announced the first patient enrolment and implant in the Totally Leadless CRT (TLC-AU) study using their WiSE System in combination with a leadless pacemaker. This feasibility study, conducted by Dr. Paul Gould at the Princess Alexandra Hospital in Brisbane, aims to evaluate the safety and efficacy of a totally leadless cardiac resynchronisation therapy (CRT) approach in newly diagnosed heart failure patients. The study is significant in potentially positioning WiSE as a first-line therapy, which could expand EBR's addressable market, as these patients represent approximately 75% of the CRT market. The procedure aligns with EBR's strategy to advance leadless pacing as the standard of care for heart failure treatment.

Key Points

First patient enrolment and implant in the TLC-AU study by Dr. Paul Gould.
The study uses EBR's WiSE System with a leadless pacemaker for totally leadless CRT.
TLC-AU targets newly diagnosed heart failure patients requiring CRT.
De novo patients account for around 75% of the CRT market.
The study could establish WiSE as a potential first-line CRT option.
EBR aims to strengthen leadership in wireless cardiac pacing.

IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.